Physician

Ryan Mark Proctor, D.O.

According to 2025 Medicare claims, Ryan Proctor, D.O. (NPI: 1972861326) practices dermatology in the Lake Havasu City-Kingman, AZ market, with the plurality of this provider's patient population coming from Mohave, AZ. This provider's primary affiliated billing organization is ARIZONA DESERT DERMATOLOGY AND SURGERY PC (NPI: 1386702546; TIN: 860797917) and primary practice location at 86442-7805.

Proctor's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 907 traditional Medicare patients, billed 9,981 HCPCS/CPT codes, and received $923,505 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,621 prescription claims across 580 beneficiaries totaling $574,002 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 10 records totaling $200. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $216,290 to $923,505. Similarly, Part D prescription costs have risen steadily, from $38,199 to $574,002. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$462K$924K2015 Medicare payment: $216,290 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $113,982 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $516,739 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $416,212 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $561,899 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $551,993 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $540,058 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $923,505 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20158705,056$216,290
2016N/RN/RN/R
2017N/RN/RN/R
20182571,452$113,982
20191,1999,872$516,739
20209758,533$416,212
202192310,047$561,899
20229299,455$551,993
202398010,658$540,058
20249079,981$923,505

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$287K$574K2015 Drug cost: $38,199 (USD; Tot_Drug_Cst)2016 Drug cost: $2,071 (USD; Tot_Drug_Cst)2017 Drug cost: $1,827 (USD; Tot_Drug_Cst)2018 Drug cost: $36,935 (USD; Tot_Drug_Cst)2019 Drug cost: $94,037 (USD; Tot_Drug_Cst)2020 Drug cost: $136,517 (USD; Tot_Drug_Cst)2021 Drug cost: $123,428 (USD; Tot_Drug_Cst)2022 Drug cost: $187,021 (USD; Tot_Drug_Cst)2023 Drug cost: $268,673 (USD; Tot_Drug_Cst)2024 Drug cost: $574,002 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015257634$38,199
20163954$2,071
20173347$1,827
201889153$36,935
20194211,033$94,037
20204281,085$136,517
20214491,140$123,428
20224501,247$187,021
20235691,576$268,673
20245801,621$574,002

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths345521$76
11102Biopsy of related skin growth, first growth184225$60
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more7581,930$60
17000Destruction of precancer skin growth, 1 growth458800$36
17003Destruction of precancer skin growth, 2-14 growths3492,423$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa11868$228,632
Clobetasol PropionateClobetasol Propionate481,596$3,772
Triamcinolone AcetonideTriamcinolone Acetonide3429,785$2,401
FluorouracilFluorouracil27832$2,155
Mycophenolate MofetilMycophenolate Mofetil13390$1,792

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.10$200ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ryan Mark Proctor, D.O.?

Tedicare shows public-source Medicare data for Ryan Mark Proctor, D.O. (NPI 1972861326), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ryan Mark Proctor, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ryan Mark Proctor, D.O.?

Ryan Mark Proctor, D.O. is linked to ARIZONA DESERT DERMATOLOGY AND SURGERY PC (billing NPI 1386702546) in the available physician profile data.

Does Ryan Mark Proctor, D.O. have Open Payments data?

Ryan Mark Proctor, D.O. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.